HTFL trades 3.8% below Wall Street's consensus target of $37.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes HTFL achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, Heartflow, Inc. Common Stock (HTFL) has a Wall Street consensus price target of $37.00, based on estimates from 4 covering analysts. With the stock currently trading at $35.65, this represents a potential upside of +3.8%. The company has a market capitalization of $13.14B.
Analyst price targets range from a low of $37.00 to a high of $37.00, representing a 0% spread in expectations. The median target of $37.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, HTFL trades at a trailing P/E of -111.4x. Analysts expect EPS to grow -62.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ISRGIntuitive Surgical, Inc. | $143.6B | $404.27 | $597.78 | +47.9% | Buy | 38.7x | 55 |
IRTCiRhythm Technologies, Inc. | $3.9B | $118.89 | $188.75 | +58.8% | Buy | — | 20 |
RXRXRecursion Pharmaceuticals, Inc. | $1.6B | $3.52 | $5.50 | +56.3% | Hold | — | 10 |
NVCRNovoCure Limited | $1.8B | $15.43 | $33.00 | +113.9% | Buy | — | 15 |
GEHCGE HealthCare Technologies Inc. | $29.9B | $65.76 | $81.00 | +23.2% | Buy | 13.5x | 18 |
SYKStryker Corporation | $127.4B | $332.31 | $387.46 | +16.6% | Buy | 22.2x | 51 |
BSXBoston Scientific Corporation | $65.7B | $44.23 | $82.40 | +86.3% | Buy | 13.1x | 44 |
ABTAbbott Laboratories | $163.4B | $93.82 | $126.00 | +34.3% | Buy | 17.1x | 41 |
MDTMedtronic plc | $104.0B | $80.98 | $95.80 | +18.3% | Buy | 13.6x | 51 |
NVDANVIDIA Corporation | $4.7T | $192.53 | $316.79 | +64.5% | Buy | 21.5x | 79 |
Quick answers to the most common questions about buying HTFL stock.
The consensus price target for HTFL is $37, close to the current price of $35.65 (3.8% implied move). Based on 4 analyst estimates, the stock appears fairly valued near current levels.
HTFL has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $37 implies 3.8% upside from current levels.
HTFL's current price is $35.65 with a consensus target of $37 (3.8% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $37 for HTFL, while the most conservative target is $37. The consensus of $37 represents the median expectation. These targets typically reflect 12-month expectations.
HTFL is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month HTFL stock forecast based on 4 Wall Street analysts shows a consensus price target of $37, with estimates ranging from $37 (bear case) to $37 (bull case). The median consensus rating is "Buy".
HTFL appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $37 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
HTFL analyst price targets range from $37 to $37, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $37 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.